enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.
enVVeno Medical Corporation CEO Robert Berman said that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of its VenoValve device.